Trials missing primary endpoints is fairly common. Provided the data is promising, you adjust and try again.

I have been invested in a few biotechs. Not an expert by any means.

I have concerns as well about trial designs and unforseen challenges, but what I come back to is what the doctors using Leronlimab have said.

But, until we prove it out in trials it means nothing.